Literature DB >> 21169857

The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.

Karen Lindsay1, Peter Gow, Jane Vanderpyl, Phillip Logo, Nicola Dalbeth.   

Abstract

BACKGROUND: Gout is commonly undertreated and can lead to significant disability. Few data are available about the lived experience of gout or the barriers to effective urate-lowering therapy in men with gout. AIMS: This study aims to understand the experience of men living with chronic gout using a qualitative grounded theory approach.
METHODS: Eleven English-speaking men with chronic gout participated in an in-depth semistructured interview about their experiences of living with gout. Interviews were recorded and transcribed. Consensus groups were used to analyze and validate the themes arising from the transcripts.
RESULTS: Three major themes related to the experience of gout emerged from the interviews: the impact of disease (pain, dependency on family members during flares, isolation, work disability), the progressiveness of untreated gout (increasing number of affected joints and frequency of flares, increase in food type triggers, escalating treatment required to control flares due to reducing efficacy of anti-inflammatory medication), and the lack of knowledge of gout (a community wide lack of understanding of the causes or prevention of gout, stoicism/tolerance to symptoms and disability, personal and social stigma related to gout). DISCUSSION: Chronic gout has an important impact on both the patient and his family. This work provides previously hidden perspectives of the experience of gout, which may be generalized to other men with gout, suggesting that shame, embarrassment, and stigma lead to trivialization of the impact of disease despite its severity. These experiences may lead to undertreatment of gout because of lack of disclosure of symptom severity and lack of expectation of treatment effectiveness, which in turn could contribute to the development of progressive gout.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169857     DOI: 10.1097/RHU.0b013e318204a8f9

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  49 in total

1.  Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?

Authors:  Matthew J Coleshill; Eindra Aung; Jane E Carland; Kate Faasse; Sophie Stocker; Richard O Day
Journal:  Ther Innov Regul Sci       Date:  2020-07-13       Impact factor: 1.778

Review 2.  Gout.

Authors:  Tuhina Neogi
Journal:  Ann Intern Med       Date:  2016-07-05       Impact factor: 25.391

3.  Discrepancies in how the impact of gout is assessed in outcomes research compared to how health professionals view the impact of gout, using the lens of the International Classification of Functioning, Health and Disability (ICF).

Authors:  Eveline M Kool; Marieke J Nijsten; Annelies E van Ede; Tim L Jansen; William J Taylor
Journal:  Clin Rheumatol       Date:  2016-06-14       Impact factor: 2.980

Review 4.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

5.  eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study.

Authors:  Alyssa Howren; Nicole W Tsao; Hyon K Choi; Kam Shojania; Alison Kydd; Russell Friesen; J Antonio Avina-Zubieta; Mary A De Vera
Journal:  Clin Rheumatol       Date:  2019-11-13       Impact factor: 2.980

6.  Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats.

Authors:  Rosane M S dos Santos; Sara M Oliveira; Cássia R Silva; Carin Hoffmeister; Juliano Ferreira; Jamil Assreuy
Journal:  Inflamm Res       Date:  2013-03-30       Impact factor: 4.575

7.  Allopurinol use in a New Zealand population: prevalence and adherence.

Authors:  Simon Horsburgh; Pauline Norris; Gordon Becket; Bruce Arroll; Peter Crampton; Jacqueline Cumming; Shirley Keown; Peter Herbison
Journal:  Rheumatol Int       Date:  2014-01-04       Impact factor: 2.631

8.  Clinical characteristics of foot ulceration in people with chronic gout.

Authors:  Keith Rome; Kathryn Erikson; Cynthia Otene; Hazra Sahid; Karyn Sangster; Peter Gow
Journal:  Int Wound J       Date:  2014-03-28       Impact factor: 3.315

9.  A qualitative and quantitative analysis of the characteristics of gout patient education resources.

Authors:  Philip C Robinson; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-01-16       Impact factor: 2.980

10.  Goals of gout treatment: a patient perspective.

Authors:  Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.